Amorfix Life Science (ARFXF) 0.0270 $ARFXF IIROC Trade

New Post Public Reply Private Reply Replies (0) Message Board

May 19, 2015 at 2:03 AM

Amorfix Life Science (ARFXF) 0.0270 $ARFXF

IIROC Trade Halt - Amorfix Life Sciences Ltd.
Newsfile Corp - Mon Jan 12, 8:12PM CST
The following issues have been halted by IIROC:

IIROC Trade Resumption - Amorfix Life Sciences Ltd.
Newsfile Corp - Mon Jan 12, 8:12PM CST
Trading resumes in:

Amorfix announces strategic plan to centralize operations in South San Francisco and focus on neurodegenerative disease
CNW Group - Mon Jan 12, 8:30AM CST
TSX: AMF
AMF.TO: 0.04 (+0.01)

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 126.02 (+3.24), CLDX: 26.26 (+0.45), CYCC: 0.77 (-0.04), IMMU: 4.22 (+0.10), EBS: 30.91 (+0.19), INCY: 107.65 (+0.79), TGTX: 16.22 (unch), AMGN: 163.44 (+1.08), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), GILD: 111.00 (+1.70), CELGZ: 2.60 (unch)

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rd5zp/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - AB Science - Aestus Therapeutics - AlzProtect - Amorfix Life Sciences - Anavex Life Sciences - Angion Biomedica - Apodemus - BBB Therapeutics - BioCrea - Biogen Idec - Bionure Farma - BrainStorm Cell Therapeutics - CalAsia Pharmaceuticals - Calico - Cellceutix - Cellular Biomedicine Group - Chronos Therapeutics Limited - Cytokinetics - D-Pharm - Daval International Ltd. - Eisai Co., Ltd. - Evotec AG - ExSAR Corporation - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - Glialogix, Inc. - Grifols, S.A. - Herantis Pharma plc. - ImStar Therapeutics Inc. - Jeil Pharmaceutical Co., Ltd. - Kadimastem Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - Maas Biolab - Mallinckrodt plc - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Holding AG - Neurodyn Inc. - Neurotec Pharma SL - Neurotune AG - Newron Pharmaceuticals S.p.A. - Nexgenix Pharmaceuticals, LLC - Orphazyme ApS - Paladin Labs Inc. - Pharnext SAS - Q Therapeutics, Inc. - Regenesance BV - reMYND - RhinoCyte, Inc. - RXi Pharmaceuticals Corporation - Saneron CCEL Therapeutics, Inc. - SK Biopharmaceuticals Co., Ltd. - Spherium biomed S.L. - Varinel, Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9r...myotrophic
BIIB: 395.42 (+4.18), KNMD: (), GSK: 44.66 (-0.11), BCLI: 3.59 (-0.07), CBMG: 29.54 (+2.04), CUR: 1.71 (+0.01)

Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 13.07 (+0.41), INO: 8.11 (+0.14), ADXS: 20.90 (+0.82), GSK: 44.66 (-0.11), NKTR: 11.32 (+0.19), NVS: 104.06 (+0.31)

Amorfix announces fiscal 2014 year end results
CNW Group - Fri Jun 13, 5:00PM CDT
TSX: AMF
AMF.TO: 0.04 (+0.01)

William Wyman appointed Amorfix Chairman of the Board
CNW Group - Thu Jun 12, 6:30AM CDT
TSX: AMF
AMF.TO: 0.04 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Luxury Vinyl Tiles Market Set for Steady Growth to 2031

Luxury Vinyl Tiles: A Market on the Rise Well, folks, the flooring game is picking up steam, and luxury vinyl tiles (LVT) are in the spotlight. With consumers and businesses all looking for something durable yet easy on the eyes and wallet, LVT is answering the call. MarketsandMarkets™ reports that this sector is expected to balloon from USD 18.22 billion in 2026 to USD...

Windward Expands Maritime Scope with Azimut.ai Deal

An Invincible Maritime Shield When it comes to maritime intelligence, Windward just pulled a fast one. In a market where staying ahead of the game is like playing three-dimensional chess, they've snatched up Azimut.ai. This ain't some small fry; it's a visual intelligence firm poised to shore up Windward's grip on the elusive maritime world. Charting New Waters with...

Lumentum Holders Question Marvell Deal Fairness: Legal Eyes

What's Brewing with Lumentum and Marvell? There's no denying the chatter on Wall Street when there's a potential shake-up, especially with a big merger at stake. We're staring down the barrel of an investigation concerning Lumentum Holdings Inc. (NASDAQ: LITE) and Marvell Technology, Inc.'s deal. The M&A Class Action Firm, helmed by Juan Monteverde, is the name leading...

Tellus Offers Seamless Security with Passkey Sign-In

Tellus Brings a New Era of Convenience Even the most innovative, forward-thinking companies occasionally have to change step to keep up with the relentless march of technology. That's what Tellus App, Inc., a proptech company from Silicon Valley, is doing with its latest announcement to offer passkey sign-ins for its savings app across iOS, Android, and the web. In...

Sunrate's Bold Move: New Payment Bond with Netstorming

Sunrate Joins Forces with Netstorming When two industry powerhouses shake hands, it's wise to sit up and listen. Sunrate, the global whiz in payment solutions, has linked arms with Netstorming, a tech-savvy pioneer in the travel sector. This ironclad partnership was announced at World Travel Market London 2026. Owners of travel businesses should take note: things are...

Latham's Strategic Growth with 70 New Counsel Roles

Grit Meets Growth at Latham & Watkins There's grit, then there's growth, and Latham & Watkins seems hell-bent on showcasing both. Promoting 70 associates to the rank of counsel is no small feat, folks. This ain't your run-of-the-mill law firm shuffle; it's a calculated expansion with teeth. Effective January 1, 2027, these promotions will rope in legal heavyweights from...

Fire Pro Shop Tackles Lumber Mold With New Campaign

Addressing Mold Where It Matters Lumber, my friends, has always been at the mercy of the elements. Rain, snow, and everything in between turn it into a sponge, especially during construction, and that's a mold risk that sneaks up faster than a bear market dive. Fire Pro Shop’s latest baby, the Snap-Plate Mold Defender, isn’t just another product—it’s a savior for...

HikTech Star Tour Highlights Co-Innovation at Hikvision

Innovation Meets Collaboration at HikTech Star Tour Ever been to one of those tech expos that's more about hype than substance? No smoke and mirrors here. The 2026 HikTech Star Tour wasn’t your run-of-the-mill tech meet-up. Held in Hangzhou, the event brought together 130 tech professionals from 56 countries. It’s like a digital United Nations, but with fewer speeches...

CFDA Fashion Awards: Stars Align for High-Stakes Night

A Night of Glamour and Recognition Fashion's upper crust pulled out all the stops at the 2026 CFDA Fashion Awards, presented by Amazon Fashion. Amidst glittering gowns and sharp tuxedos, recognition was the order of the night at an event held at the American Museum of Natural History. What you got was an industry tip of the hat to the visionaries pushing boundaries in...

Qapture's Institutional Stablecoin Venture Unveiled

Stablecoin Strategy Meets Institutional Investment Here's a fresh one from the digital asset universe. We're talking about Qapture Investments' bold move to launch an institutional-grade stablecoin yield strategy. This ain't your average kitchen table crypto chat—it's the Qapture Safe Haven Vault (QHVN-USD), tailored for those looking to get a better return on their...